Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

For Women With Genetic Risk, Twice-A-Year MRI Beats Mammograms

September 18, 2018 By University of Chicago Medical Center

Getting magnetic resonance imaging (MRI) scans twice a year instead of one annual mammogram is far more effective at detecting early breast cancers in young women with a high-risk genetic profile than mammograms alone, according to a research team based at the University of Chicago Medicine and the University of Washington, Seattle.

The results, first presented last year at the annual San Antonio Breast Cancer Symposium and now available online in Clinical Cancer Research, suggest that for women with high-risk genetic mutations, intensive efforts to find small early cancers can be crucial to improving outcomes.

“This study demonstrates for the first time that aggressive breast cancers can be caught early, without excessive recalls or biopsies,” says Olufunmilayo Olopade, MD, the Walter L. Palmer Distinguished Service Professor and Associate Dean for Global Health at the University of Chicago Medical Center.

Because of intensive surveillance and high-quality care, the majority of high-risk women in this study did not develop breast cancer, despite the fact that most of these women had genetic mutations such as BRCA1.

For their study, “Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers,” the researchers enrolled 295 women into a clinical trial. The mean age at entry was 43.3 years.

To join the trial, volunteers had to have a lifetime risk for breast-cancer greater than 20 percent. More than half (53 percent) of the women who enrolled had one of 11 known breast-cancer related genetic abnormalities. Seventy-five of those 157 women had BRCA1 mutations, and 61 had BRCA2 mutations.

The study also included women who had been diagnosed with breast cancer or ductal carcinoma in situ before age 35, or had a mother or sister diagnosed with breast cancer before age 50 (before 40 for those of African ancestry). All study subjects had a panel of genetic tests looking for genes associated with a predisposition to breast cancer.

DCE-MRI every six months performed well for early detection of invasive breast cancer in genomically stratified high-risk women. (Image credit: Fred Pineda, postdoctoral fellow, the University of Chicago Medicine)

After evaluation by a physician and a genetic counselor, participants were scheduled to undergo a clinical breast examination and a dynamic contrast-enhanced magnetic resonance imaging scan (DCE-MRI) every six months, plus a digital mammogram every 12 months. Those with high-risk mutations who completed five years of the study protocol were offered continued screening.

Over the course of the study, the researchers performed 2,111 DCE-MRIs (on average, about seven for each participant) and 1,223 mammograms (four per participant). They found 17 cancers: four ductal carcinoma in situ and 13 early stage breast cancers.

Fifteen of those cancers occurred in participants with pathogenic mutations. Eleven involved BRCA1, three involved BRCA2, and one involved CDH1. None of the cancers had spread to the lymph nodes. The mean tumor size was 0.61 centimeter (about 1/4 of an inch). All cancers detected during the study were smaller than a centimeter.

The 17 patients who developed a cancer were followed continuously for a median of 5.3 years (range 0.5 to 11 years). All are alive and free of systemic disease. Patient anxiety levels decreased over time and patient-reported quality of life improved. The study authors recommend “further interventional studies evaluating this novel screening approach to personalize breast cancer risk assessment and prevention.”

In this study, DCE-MRI every 6 months “performed well for early detection of invasive breast cancer in genomically stratified high-risk women,” says Gregory Karczmar, PhD, professor of radiology at the University of Chicago. “This is the ultimate goal of breast cancer screening,” he added, “detecting node-negative, invasive tumors less than 1 centimeter.”

“For these patients, annual mammography did not provide any additional benefit to bi-annual dynamic contrast-enhanced MRI scans,” the authors agree.

Mammograms are routinely used to screen for breast cancer, but they are “not the best option for about 40 percent of women,” Karczmar says. “This includes those with dense breasts as well as those with significant genetic risks. MRI is much more sensitive than mammography. It can find invasive breast cancers sooner than mammograms and it can rule out abnormalities that appear suspicious on a mammogram. Unfortunately, MRI is much too expensive for routine screening.”

Mammograms will remain important for most women, but for women at high risk who are getting a DCE-MRI every six months, “annual mammograms can be eliminated,” Olopade says.

“The central goal of our study was to understand the needs of the highest-risk women,” says study co-author Mary Claire King, PhD, professor of genome sciences and of medicine at the University of Washington and the American Cancer Society Research Professor for Breast Cancer.

King has advocated for all women to be offered testing for BRCA1 and BRCA2 at about age 30, regardless of personal or family history of cancer, so that women with mutations can take action to prevent cancer in their futures.

“My hope is that mammography and MRI will be used in ways that make sense given a woman’s personal genetics,” she says. “Women with mutations in BRCA1 or BRCA2 have very different needs for surveillance for breast disease than women with no mutations in these genes. This is particularly true for healthy young women with mutations. It’s truly critical to offer intensive surveillance to still-healthy women with BRCA1 or BRCA2 mutations.”

A number of patients withdrew from the study within five years. Their primary reasons for leaving were the cost of health insurance or other payment issues, 27 percent; prophylactic mastectomy, 16 percent; and moved away or changed healthcare provider, 11 percent.

The American Cancer Society (ACS) currently recommends an annual DCE-MRI as well as an annual mammogram for women who are at high risk, typically starting at age 30.

Related Articles Read More >

The Virtuoso System endoscope tip with manipulators,
Tiny, superelastic nitinol arms make this breakthrough surgical robot possible
An illustration showing the Autus size-adjustable heart valve being expanded years after implantation with a minimally invasive balloon catheter.
The first-of-its-kind Autus pediatric heart valve is designed for expansion and durability
J&J EP leader Michael Bodner offers a PFA program update
The MIT researcher's implant, LUCID.
MIT researchers design implantable ultrasound-powered drug delivery device to minimize tumor recurrence
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 Arrowfly, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe